122 related articles for article (PubMed ID: 9450573)
21. Vitamin D receptor: a potential target for intervention.
Johnson CS; Hershberger PA; Bernardi RJ; Mcguire TF; Trump DL
Urology; 2002 Sep; 60(3 Suppl 1):123-30; discussion 130-1. PubMed ID: 12231068
[TBL] [Abstract][Full Text] [Related]
22. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
23. Responsiveness of the intestinal 1,25-dihydroxyvitamin D3 receptor to magnesium depletion in the rat.
Lemay J; Gascon-Barré M
Endocrinology; 1992 May; 130(5):2767-77. PubMed ID: 1315257
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines.
Kawa S; Yoshizawa K; Tokoo M; Imai H; Oguchi H; Kiyosawa K; Homma T; Nikaido T; Furihata K
Gastroenterology; 1996 May; 110(5):1605-13. PubMed ID: 8613068
[TBL] [Abstract][Full Text] [Related]
25. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo.
Verone-Boyle AR; Shoemaker S; Attwood K; Morrison CD; Makowski AJ; Battaglia S; Hershberger PA
Oncotarget; 2016 Jan; 7(1):995-1013. PubMed ID: 26654942
[TBL] [Abstract][Full Text] [Related]
26. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
27. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers.
Kim S; Yamazaki M; Zella LA; Shevde NK; Pike JW
Mol Cell Biol; 2006 Sep; 26(17):6469-86. PubMed ID: 16914732
[TBL] [Abstract][Full Text] [Related]
28. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin.
Li XY; Boudjelal M; Xiao JH; Peng ZH; Asuru A; Kang S; Fisher GJ; Voorhees JJ
Mol Endocrinol; 1999 Oct; 13(10):1686-94. PubMed ID: 10517670
[TBL] [Abstract][Full Text] [Related]
29. [The influence of isoflavonoids on the antitumor activity of vitamin D3].
Wietrzyk J
Postepy Hig Med Dosw (Online); 2007; 61():253-60. PubMed ID: 17507873
[TBL] [Abstract][Full Text] [Related]
30. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
Norman AW; Sergeev IN; Bishop JE; Okamura WH
Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; van den Bemd GJ; Dorssers LC; Birkenhäger JC; van Leeuwen JP
Cancer Res; 1994 Nov; 54(21):5711-7. PubMed ID: 7923220
[TBL] [Abstract][Full Text] [Related]
32. Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191).
Wietrzyk J; Pełczyńska M; Madej J; Dzimira S; Kuśnierczyk H; Kutner A; Szelejewski W; Opolski A
Steroids; 2004 Sep; 69(10):629-35. PubMed ID: 15465107
[TBL] [Abstract][Full Text] [Related]
33. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
El Abdaimi K; Papavasiliou V; Rabbani SA; Rhim JS; Goltzman D; Kremer R
Cancer Res; 1999 Jul; 59(14):3325-8. PubMed ID: 10416587
[TBL] [Abstract][Full Text] [Related]
34. Biologic activity of dihydroxylated 19-nor-(pre)vitamin D3.
Bouillon R; Sarandeses LA; Allewaert K; Zhao J; Mascareñas JL; Mouriño A; Vrielynck S; de Clercq P; Vandewalle M
J Bone Miner Res; 1993 Aug; 8(8):1009-15. PubMed ID: 8213251
[TBL] [Abstract][Full Text] [Related]
35. 1,25 dihydroxyvitamin D and dexamethasone decrease in vivo Walker carcinoma growth, but not parathyroid hormone related protein secretion.
Cohen-Solal ME; Bouizar Z; Denne MA; Graulet AM; Gueris J; Bracq S; Jullienne A; de Vernejoul MC
Horm Metab Res; 1995 Sep; 27(9):403-7. PubMed ID: 8557238
[TBL] [Abstract][Full Text] [Related]
36. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.
Hershberger PA; Yu WD; Modzelewski RA; Rueger RM; Johnson CS; Trump DL
Clin Cancer Res; 2001 Apr; 7(4):1043-51. PubMed ID: 11309356
[TBL] [Abstract][Full Text] [Related]
37. Herbimycin A, a tyrosine kinase inhibitor, impairs hypercalcemia associated with a human squamous cancer producing interleukin-6 in nude mice.
Moriyama K; Williams PJ; Niewolna M; Dallas MR; Uehara Y; Mundy GR; Yoneda T
J Bone Miner Res; 1996 Jul; 11(7):905-11. PubMed ID: 8797110
[TBL] [Abstract][Full Text] [Related]
38. Zoledronate-responsive calcitriol-mediated hypercalcemia in a 5-year-old case with squamous cell carcinoma on the background of xeroderma pigmentosum.
Colak U; Mutlu GY; Sozmen BO; Yucel EB; Kayserili H; Hatun S
J Pediatr Endocrinol Metab; 2019 Dec; 32(12):1403-1406. PubMed ID: 31782950
[TBL] [Abstract][Full Text] [Related]
39. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3.
Shabahang M; Buras RR; Davoodi F; Schumaker LM; Nauta RJ; Uskokovic MR; Brenner RV; Evans SR
Cancer Res; 1994 Aug; 54(15):4057-64. PubMed ID: 8033137
[TBL] [Abstract][Full Text] [Related]
40. Eldecalcitol (ED-71), an analog of 1α,25(OH)
Shintani T; Takatsu F; Rosli SNZ; Usui E; Hamada A; Sumi K; Hayashido Y; Toratani S; Okamoto T
In Vitro Cell Dev Biol Anim; 2017 Oct; 53(9):810-817. PubMed ID: 28710602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
